Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Raltegravir

Nature Reviews Drug Discovery volume 7, pages 117–118 (2008)Cite this article

Abstract

In October 2007, raltegravir (Isentress; Merck), a small-molecule drug that inhibits HIV-1 integrase, became the first drug in its class to be approved by the US FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Integrase inhibitors.

References

  1. Flexner, C. HIV drug development: the next 25 years. Nature Rev. Drug Discov. 6, 959–966 (2007).

    Article  CAS  Google Scholar 

  2. Pommier, Y. et al. Integrase inhibitors to treat HIV/AIDS. Nature Rev. Drug Discov. 4, 236–248 (2005).

    Article  CAS  Google Scholar 

  3. Hazuda, D. J. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287, 646–650 (2000).

    Article  CAS  Google Scholar 

  4. Hazuda, D. J. et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305, 528–532 (2004).

    Article  CAS  Google Scholar 

  5. Summa, V. et al. Discovery of MK-0518 a novel, potent and selective HIV integrase inhibitor in phase III clinical trials. 16th International AIDS Conference Aug 13–18 2006; 16 Abstract No. ThPe0020. International AIDS Society web site [online], (2006).

    Google Scholar 

  6. Food and Drug Administration. FDA labelling information [online], (2007).

  7. Grinsztejn, B. et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369, 1261–1269 (2007).

    Article  CAS  Google Scholar 

  8. Markowitz, M. et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune. Defic. Syndr. 46, 125–133 (2007).

    Article  CAS  Google Scholar 

  9. Claxton, A.J., Cramer, J. & Pierce, C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23, 1296–1310 (2001).

    Article  CAS  Google Scholar 

  10. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (1–143). Department of Health and Human Services web site [online], (2007).

  11. Moore, D. M. et al. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 20, 371–377 (2006).

    Article  CAS  Google Scholar 

  12. Hunt, P. W. et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 187, 1534–1343 (2003).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Steven Deeks is at the University of California, San Francisco, 995 Potrero Avenue, San Francisco, California 94110, USA. sdeeks@php.ucsf.edu,

    Steven G. Deeks

  2. Santwana Kar and Steven I. Gubernick are at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. skar@uk.imshealth.com,

    Santwana Kar & Steven I. Gubernick

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Steven G. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Santwana Kar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven I. Gubernick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Steven Deeks has served as an ad hoc consultant for Tibotec and Boehringer Ingelheim, and is the principal investigator on studies partially funded by Merck and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deeks, S., Kar, S., Gubernick, S. et al. Raltegravir. Nat Rev Drug Discov 7, 117–118 (2008). https://doi.org/10.1038/nrd2512

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2512

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing